Zacks Investment Research·2d ago
Best Momentum Stocks to Buy for September 21stSEI, SDRL and PAHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 21st, 2026.
Phibro Animal Health's revenue growth has accelerated to 39.7% year-over-year in Q1 2026, driven by the strategic acquisition of Zoetis' medicated feed additive portfolio, which has expanded its market position. However, this growth has been accompanied by a s...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 26, 2026 | $0.85+19.2% vs $0.71 | $397M+4.1% vs $381M |
Q2 2026 May 6, 2026 | $0.76+5.6% vs $0.72 | $384M+4.5% vs $367M |
Q1 2026 Feb 4, 2026 | $0.87+26.1% vs $0.69 | $374M+5.1% vs $356M |
Q4 2025 Nov 5, 2025 | $0.73+23.7% vs $0.59 | $364M+4.9% vs $347M |
SEI, SDRL and PAHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 21st, 2026.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
Engineers Gate Manager LP boosted its position in Phibro Animal Health Corporation (NASDAQ: PAHC) by 112.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 52,914 shares of the company's stock after purchasing an additional 28,052 shares during the quarter.
DiamondRock Hospitality, Vertiv, Mueller Water Products and Phibro Animal Health stand out for strong interest coverage as Treasury yields rise.
Benchmark PAHC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Phibro Animal Health Corporation (PAHC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.10 | $1.38B | 28.66 | 27.37% | 3.72% | 17.8% | 1.4% | |
| $22.58 | $11.28B | -48.04 | 6.22% | -3.96% | -3.02% | — | |
| $71.63 | $30.03B | 11.90 | 2.28% | 27.49% | 69.25% | — | |
| $13.57 | $2.95B | -339.25 | -2.71% | -0.91% | -0.37% | — | |
| $522.02 | $41.18B | 39.91 | 10.42% | 25.03% | 71.96% | — | |
| $51.36 | $18.21B | 37.76 | 2.12% | 1.03% | 3.15% | — |
Phibro Animal Health Corporation (PAHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Phibro Animal Health Corporation (PAHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 26, 2026·SEC
May 6, 2026·SEC
May 5, 2026·SEC
Get notified when PAHC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Phibro Animal Health Corporation (PAHC) stock FAQ — growth, dividends, profitability & financials explained
Phibro Animal Health Corporation (PAHC) reported $1.52B in revenue for fiscal year 2025. This represents a 370% increase from $323.0M in 2000.
Phibro Animal Health Corporation (PAHC) grew revenue by 27.4% over the past year. This is strong growth.
Yes, Phibro Animal Health Corporation (PAHC) is profitable, generating $99.7M in net income for fiscal year 2025 (3.7% net margin).
Yes, Phibro Animal Health Corporation (PAHC) pays a dividend with a yield of 1.40%. This makes it attractive for income-focused investors.
Phibro Animal Health Corporation (PAHC) has a return on equity (ROE) of 17.8%. This is reasonable for most industries.
Phibro Animal Health Corporation (PAHC) generated $9.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
